Global Asthma Disease Market 2025–2029: Competitive Insights and Opportunities

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Asthma Disease Industry By The Forecast Year 2029?

The asthma disease market has experienced robust growth over the past few years. Forecasts indicate its expansion from $24.63 billion in 2024 to $25.93 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 5.3%. This historical expansion stems from several factors, including the increasing prevalence of asthma among urban populations, elevated air pollution in industrialized areas, heightened awareness regarding asthma symptoms and diagnosis, the increased adoption of corticosteroids and bronchodilators, and improved healthcare accessibility in emerging economies.

The asthma disease market is projected to experience robust expansion over the coming years. This market is set to reach $31.56 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.0%. This anticipated growth during the forecast period is fueled by factors such as the increasing uptake of biologics for severe asthma, a rising demand for personalized medicine, growing investments in asthma research, the broader adoption of digital health and remote monitoring, and the expansion of telemedicine services for effective asthma management. Key trends anticipated within this period encompass advancements in biologic therapies specifically for severe asthma, the emergence of advanced inhaler technologies incorporating smart features, the creation of AI-based tools for asthma monitoring, novel approaches in personalized asthma treatment, and the development of digital health platforms designed for remote asthma management.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25701&type=smp

What Are The Main Drivers Boosting The Asthma Disease Industry’s Expansion?

The increasing incidence of respiratory ailments is expected to drive the growth of the asthma disease market in the future. Respiratory disorders encompass a range of conditions that affect the lungs and breathing, including chronic obstructive pulmonary disease (COPD), bronchitis, and asthma. The rising occurrence of these disorders is attributed to particulate matter and nitrogen oxides irritating and inflaming the airways, which leads to breathing difficulties and the worsening of conditions such as asthma. Respiratory diseases can cause inflammation and structural changes in the airways, either triggering or exacerbating asthma symptoms. For instance, in December 2023, the National Library of Medicine, a US-based national library, reported that by 2050, chronic obstructive pulmonary disease (COPD) cases in low- and middle-income countries are projected to more than double those in high-income countries, with sub-Saharan Africa anticipated to see a 59% increase and lead globally in COPD prevalence and cases by 2040. Therefore, the growing prevalence of respiratory disorders is stimulating the expansion of the asthma disease market.

How Is The Asthma Disease Market Segmented?

The asthma disease market covered in this report is segmented –

1) By Treatment Type: Controller Medications, Rescue Medications, Biologics, Combination Therapy

2) By Cause Of Asthma: Allergic Asthma, Non-Allergic Asthma, Exercise-Induced Asthma, Occupational Asthma

3) By Severity: Mild Intermittent, Mild Persistent, Moderate Persistent, Severe Persistent

4) By Route Of Administration: Oral, Inhaled, Intravenous, Other Route Of Administration

5) By End-Users: Hospitals, Homecare, Specialty Clinics , Others End-Users

Subsegments:

1) By Controller Medications Inhaled Corticosteroids (ICS), Long-Acting Beta-Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Long-Acting Muscarinic Antagonists (LAMA), Methylxanthines

2) By Rescue Medications: Short-Acting Beta-Agonists (SABA), Systemic Corticosteroids, Anticholinergics

3) By Biologics: Anti-IGE Therapy, Anti-IL-5 Therapy, Anti-IL-4/IL-13 Therapy, Anti-TSLP Therapy

4) By Combination Therapy: ICS Or LABA Combinations, ICS Or LABA Or LAMA Combinations, ICS Or LAMA Combinations

What Are The Major Trends Driving The Growth Of The Asthma Disease Market?

Leading companies in the asthma disease market are concentrating on developing solutions like monoclonal antibody therapies to improve treatment effectiveness and patient outcomes. Monoclonal antibody therapy is a type of targeted treatment that employs laboratory-made proteins to mimic the immune system’s capacity to combat harmful pathogens, thereby offering more precise and effective management for chronic conditions such as asthma. For example, in June 2022, the National Institutes of Health (NIH), a US-based medical research agency, initiated the PANDA trial (preventing asthma in high-risk kids) to assess the monoclonal antibody dupilumab as a therapy for asthma in urban youth. The PANDA trial is a Phase 2, randomized, placebo-controlled study that evaluates dupilumab in approximately 240 children aged 6–17 who have poorly controlled, type 2 inflammation, high allergic asthma and reside in low-income urban areas. Participants receive subcutaneous injections every two weeks for one year alongside standard asthma care, with a 2:1 randomization to dupilumab or placebo. The trial also encompasses mechanistic studies using nasal swabs and blood samples to analyze gene expression, particularly during respiratory viral infections, with the aim of understanding the molecular pathways of asthma exacerbations and treatment response within this high-risk pediatric population.

Which Global Market Leaders Are Shaping The Future Of The Asthma Disease Sector?

Major companies operating in the asthma disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, Generate Biomedicines.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/asthma-disease-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Asthma Disease Market?

North America was the largest region in the asthma disease market in 2024. The regions covered in the asthma disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Asthma Disease Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25701&type=smp

Browse Through More Reports Similar to the Global Asthma Disease Market 2025, By The Business Research Company

Asthma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Anti Asthmatics And Copd Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795